These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29330109)

  • 1. Friend or Foe: MicroRNAs in the p53 network.
    Luo Z; Cui R; Tili E; Croce C
    Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs as Key Effectors in the p53 Network.
    Goeman F; Strano S; Blandino G
    Int Rev Cell Mol Biol; 2017; 333():51-90. PubMed ID: 28729028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.
    Pappas K; Xu J; Zairis S; Resnick-Silverman L; Abate F; Steinbach N; Ozturk S; Saal LH; Su T; Cheung P; Schmidt H; Aaronson S; Hibshoosh H; Manfredi J; Rabadan R; Parsons R
    Mol Cancer Res; 2017 Aug; 15(8):1051-1062. PubMed ID: 28483946
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.
    Li XL; Jones MF; Subramanian M; Lal A
    FEBS Lett; 2014 Aug; 588(16):2610-5. PubMed ID: 24726728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
    Pfister NT; Prives C
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [miR-34s--a tumor suppression protein p53 highly related microRNA].
    Lou WJ; Chen Q; Liu L; Qian C
    Yi Chuan; 2010 May; 32(5):423-30. PubMed ID: 20466628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.
    Garibaldi F; Falcone E; Trisciuoglio D; Colombo T; Lisek K; Walerych D; Del Sal G; Paci P; Bossi G; Piaggio G; Gurtner A
    Oncogene; 2016 Jul; 35(29):3760-70. PubMed ID: 26996669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.
    Gurtner A; Falcone E; Garibaldi F; Piaggio G
    J Exp Clin Cancer Res; 2016 Mar; 35():45. PubMed ID: 26971015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
    McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
    Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
    Do MT; Kim HG; Choi JH; Jeong HG
    Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Control of p53.
    Liu J; Zhang C; Zhao Y; Feng Z
    J Cell Biochem; 2017 Jan; 118(1):7-14. PubMed ID: 27216701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.
    Wang W; Cheng B; Miao L; Mei Y; Wu M
    Cell Death Dis; 2013 Apr; 4(4):e574. PubMed ID: 23559009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.
    Towers CG; Guarnieri AL; Micalizzi DS; Harrell JC; Gillen AE; Kim J; Wang CA; Oliphant MUJ; Drasin DJ; Guney MA; Kabos P; Sartorius CA; Tan AC; Perou CM; Espinosa JM; Ford HL
    Nat Commun; 2015 Dec; 6():10077. PubMed ID: 26687066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour suppression by p53: the importance of apoptosis and cellular senescence.
    Zuckerman V; Wolyniec K; Sionov RV; Haupt S; Haupt Y
    J Pathol; 2009 Sep; 219(1):3-15. PubMed ID: 19562738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mutant p53 in cancer: a long road to precision therapy.
    Mantovani F; Walerych D; Sal GD
    FEBS J; 2017 Mar; 284(6):837-850. PubMed ID: 27808469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
    Neilsen PM; Noll JE; Mattiske S; Bracken CP; Gregory PA; Schulz RB; Lim SP; Kumar R; Suetani RJ; Goodall GJ; Callen DF
    Oncogene; 2013 Jun; 32(24):2992-3000. PubMed ID: 22797073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 in cancer: new functions and therapeutic opportunities.
    Muller PA; Vousden KH
    Cancer Cell; 2014 Mar; 25(3):304-17. PubMed ID: 24651012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.